Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. - Wikidata - awgldk - TriplyDB

Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.

Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q33787691

about

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage Hepatic steatosis and Type 2 diabetes: current and future treatment considerations.Recent advances in understanding/management of non-alcoholic steatohepatitis.Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease Non invasive tools for the diagnosis of liver cirrhosis.Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: a prospective study.Keratin 18 phosphorylation as a progression marker of chronic hepatitis B.Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children.Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis.Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX.Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.Diagnosis and evaluation of nonalcoholic fatty liver disease.Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease.Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis.Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes.Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans.Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease.Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure.Nonalcoholic fatty liver disease: a review and update.Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Nonalcoholic fatty liver disease: a challenge for pediatricians.Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis.Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan.Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease.Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.

P2860

Q24649618-D86EC738-EC21-4ED0-AA41-B9704734BAF9 Q24657221-CCF0D816-B105-4BA7-A07B-CD0BF1D29482 Q26773289-4AEE887F-44CC-406F-9F82-3D814A8DC2B3 Q27691399-A0465535-7E24-49C8-8A29-90D36CEE2BAB Q28085689-C73AF68F-4748-42FC-B91A-C16AE42D2036 Q28275665-E983A1A3-15E9-43B7-A9E6-A40AB4684298 Q28392515-D5588394-2937-4DB6-934E-24ED5B28371B Q28542723-9421CDBD-F54E-4D8A-896C-9828DAE47AC4 Q28550881-2056BF28-CA89-4751-920C-77664A30B5F9 Q30421450-EEC531DB-C5F0-4E56-99A3-2BB8B847990C Q30435948-14C41FCC-1E2D-4A10-8D4E-6296CEF054F4 Q30464608-0BB09388-08A4-4A1C-B06B-8F41D26BCB53 Q33332059-AB979222-771A-497B-8B90-0DFEFAC39578 Q33784854-A4B1C189-1BE3-43B2-BD48-CA27AB887C0E Q34207845-056DF810-25D8-4861-B7B8-5EDBB4D9F8CB Q34256132-16B85898-ACD4-4E9F-9E61-0F22A02A7C1F Q34414807-886989D7-C171-410E-83D3-2B3C263651F2 Q34551475-480E6F96-FB75-400D-A506-66874D44BCE2 Q34769910-5CA81B09-132A-465F-9451-C0F8BAC75EE9 Q34802423-194F9441-ED01-48A6-AB92-8D2E3F3EB09E Q34819164-C60A0211-AF07-422E-944C-1C45300E7095 Q34830398-A50D0177-C965-42AB-A917-0226AB92C2E9 Q35101419-7E784BA1-4189-4BBD-93E1-F4609B13A27B Q35495753-32E3F973-CA42-4655-8744-AC617A0EF4DD Q36116130-20E3BA24-09FA-49C6-92C2-9C97CFC2505F Q36600213-57B8F631-77E9-4BE3-8CAF-AAD14BE397E6 Q36669223-8F099019-C9AD-4BDC-8342-BD5379FCA578 Q36799716-C2F50033-3B70-4F7B-B25F-B4A669E4B8F5 Q36871971-7686D665-02D0-4245-AB53-D47E11D90577 Q37241524-DA8867C2-9B31-4772-BD3D-034854DBE461 Q37599777-629AC264-3A42-4E2A-B9E1-C7295E5D1CA9 Q37600924-94BE10B9-9716-4DDB-8C76-CB44ED25D7D4 Q37617999-6BD86C05-2627-4371-AA2A-C81ADDB3287F Q37681360-E029F8FF-6CB9-49A6-85AB-0CB7FD825F30 Q37689828-01909EEB-0100-42E0-B6F4-2F0875223DC8 Q37788538-C12C2AA8-B69C-4C18-89FB-0B408BED8039 Q37811071-1EED3FCD-7845-4091-B459-CDA5503CAF02 Q37825659-C63C16B7-46EE-42F6-91E8-20D2276BF7F4 Q37850490-ED093C1F-988C-412B-A6DB-88F0FE2E096F Q37863133-417CAD06-60E4-4FBC-987E-DF750EB8EBFC

P2860

Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q33787691

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Soluble forms of extracellular ...... nonalcoholic steatohepatitis.

@ast

Soluble forms of extracellular ...... nonalcoholic steatohepatitis.

@en

type

label

Soluble forms of extracellular ...... nonalcoholic steatohepatitis.

@ast

Soluble forms of extracellular ...... nonalcoholic steatohepatitis.

@en

prefLabel

Soluble forms of extracellular ...... nonalcoholic steatohepatitis.

@ast

Soluble forms of extracellular ...... nonalcoholic steatohepatitis.

@en

P1433

Q33787691-F7672BEA-D5E0-4724-A961-A9BF61E8288A

P1476

Q33787691-6B6A85A7-B7B8-45C3-9FF7-B1A3F82C55E4

P2093

Q33787691-0058FB39-FD32-455A-A4BF-C5F9C014C2D0

Q33787691-23F0BA76-FC02-4284-89FB-45DD32215FBC

Q33787691-3E4DC2ED-9AD7-4325-82FF-78D1755F17E9

Q33787691-4C477233-8D69-4572-A382-9DF2CDDBC04D

Q33787691-53F4ACAE-9E2A-4427-96D3-AB2D685FF375

Q33787691-72C0A1E6-216A-40AB-8EF2-7674A843D786

Q33787691-88C10B02-BB77-4BF0-A20A-3412D9CEFAE0

Q33787691-8F2D20D6-6104-410E-AA44-6B0468D6C36B

Q33787691-9A46F32C-FC43-4522-B5D4-AA06BEE2EACB

Q33787691-B3FE9994-89FE-4156-8841-E39C98E8C572

P2860

Q33787691-05E3FA8B-6ABB-4933-8FCB-699ACEAEBB7B

Q33787691-0A8D4247-E4F3-49EA-AFAD-DFCC6307E760

Q33787691-0B88CEDE-8A2D-40F6-A925-896A33D8F30D

Q33787691-14FE72E9-DE88-4A13-9033-30B3C709B73B

Q33787691-1D983BA4-5812-4DF8-BF54-7AC358057D9C

Q33787691-1FF90DD4-3AA9-429D-87FD-EED9FA649B29

Q33787691-22B8251B-4D65-47A5-8168-18C1EBC10F89

Q33787691-23332915-A2E8-43F5-AE6D-68AA777D6B9A

Q33787691-28406AF3-FBD0-4698-B4D8-81523882CE70

Q33787691-2F32B9AD-DF1A-4E07-8A60-C50A89E3230E

P304

Q33787691-35FFD8CB-6071-4107-BEAA-731580524FBA

P31

Q33787691-83A4116A-9B56-464D-94F5-CE96823894AB

P356

Q33787691-72BB76B6-D29F-46EF-BBDC-D61B75BD1841

P407

Q33787691-DB23C593-70B9-48A2-B140-6F53FF704A96

P433

Q33787691-7984F474-F79C-4392-86E4-39617987240F

P478

Q33787691-5153A0C6-15AC-47B1-9C74-00997CEC95BA

P577

Q33787691-A84B5ED0-7837-427F-B53F-24A3152ED1DE

P5875

Q33787691-7E7886AB-B336-468F-A658-BB6B5C54B288

P698

Q33787691-94D28B78-CEF4-493A-8E1F-9E3289276D5C

P921

Q33787691-2B9CDB5E-B48B-4DA2-A039-137C303A6467

P932

Q33787691-D61B1C37-54A8-4846-A2D4-24BDB67C6AC1

P356

P1433

World Journal of Gastroenterology

P1476

Soluble forms of extracellular ...... nonalcoholic steatohepatitis.

@en

P2093

Arzu Yilmaztepe

http://www.w3.org/2001/XMLSchema#string

Engin Ulukaya

http://www.w3.org/2001/XMLSchema#string

Enver Dolar

http://www.w3.org/2001/XMLSchema#string

Macit Gulten

http://www.w3.org/2001/XMLSchema#string

Murat Keskin

http://www.w3.org/2001/XMLSchema#string

Murat Kiyici

http://www.w3.org/2001/XMLSchema#string

Selim Gurel

http://www.w3.org/2001/XMLSchema#string

Selim-Giray Nak

http://www.w3.org/2001/XMLSchema#string

Semra Akgoz

http://www.w3.org/2001/XMLSchema#string

Sibel Aker

http://www.w3.org/2001/XMLSchema#string

P2860

Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Mechanisms of hepatotoxicity

Steatohepatitis: a tale of two "hits"?

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease

Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies.

The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.

Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis.

P304

837-844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V13.I6.837

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6455061

http://www.w3.org/2001/XMLSchema#string

P698

17352011

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

P932

4065917

http://www.w3.org/2001/XMLSchema#string